Adaptimmune Therapeutics (NASDAQ:ADAP) Coverage Initiated by Analysts at StockNews.com
StockNews.com has initiated coverage on Adaptimmune Therapeutics (NASDAQ:ADAP), issuing a "buy" rating. Other analysts, including Guggenheim and HC Wainwright, have also set target prices of $3.00 and $3.50, respectively, while Mizuho lowered its target to $1.50. The stock has a consensus rating of "Buy" with an average target price of $2.79. Adaptimmune Therapeutics, a clinical-stage biopharmaceutical company, focuses on novel cell therapies for cancer patients. The stock opened at $0.46, with a market cap of $118.14 million and a PE ratio of -2.10.
Investment analysts at StockNews.com assumed coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) in a research report issued on Thursday. The brokerage set a "buy" rating on the biotechnology company's stock.
Other equities research analysts also recently issued research reports about the stock. Guggenheim cut their target price on shares of Adaptimmune Therapeutics from $4.00 to $3.00 and set a "buy" rating for the company in a research report on Friday, November 15th. HC Wainwright cut their target price on shares of Adaptimmune Therapeutics from $4.00 to $3.50 and set a "buy" rating for the company in a research report on Thursday, November 14th. Finally, Mizuho cut their target price on shares of Adaptimmune Therapeutics from $3.00 to $1.50 and set an "outperform" rating for the company in a research report on Wednesday, November 27th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $2.79.
View Our Latest Stock Analysis on ADAP
Adaptimmune Therapeutics Trading Up 3.3 %
NASDAQ:ADAP opened at $0.46 on Thursday. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.62. Adaptimmune Therapeutics has a 12 month low of $0.44 and a 12 month high of $1.70. The company has a market cap of $118.14 million, a PE ratio of -2.10 and a beta of 2.52. The company has a 50 day simple moving average of $0.57 and a two-hundred day simple moving average of $0.74.
Institutional Investors Weigh In On Adaptimmune Therapeutics
A number of hedge funds have recently modified their holdings of the business. Two Seas Capital LP bought a new stake in shares of Adaptimmune Therapeutics during the 4th quarter valued at $7,992,000. Two Sigma Investments LP grew its position in shares of Adaptimmune Therapeutics by 33.5% during the 4th quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company's stock valued at $41,000 after acquiring an additional 19,146 shares during the period. Two Sigma Advisers LP grew its position in shares of Adaptimmune Therapeutics by 492.0% during the 4th quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company's stock valued at $38,000 after acquiring an additional 58,787 shares during the period. Jane Street Group LLC grew its position in shares of Adaptimmune Therapeutics by 87.7% during the 4th quarter. Jane Street Group LLC now owns 326,937 shares of the biotechnology company's stock valued at $176,000 after acquiring an additional 152,780 shares during the period. Finally, Long Focus Capital Management LLC grew its position in shares of Adaptimmune Therapeutics by 54.1% during the 4th quarter. Long Focus Capital Management LLC now owns 20,494,393 shares of the biotechnology company's stock valued at $11,040,000 after acquiring an additional 7,194,503 shares during the period. Institutional investors own 31.37% of the company's stock.
About Adaptimmune Therapeutics
(Get Free Report)Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
See Also
- Five stocks we like better than Adaptimmune Therapeutics
- High Flyers: 3 Natural Gas Stocks for March 2022
- Ramaco Resources Pins Hopes on Coal's Untapped Potential
- Best Stocks Under $10.00
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
- What is the S&P/TSX Index?
- Why Energy Transfer Belongs on Your Watchlist
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Adaptimmune Therapeutics Right Now?
Before you consider Adaptimmune Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptimmune Therapeutics wasn't on the list.
While Adaptimmune Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
